Porton Pharma Solutions Past Earnings Performance
Past criteria checks 0/6
Porton Pharma Solutions has been growing earnings at an average annual rate of 31.9%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 28.5% per year.
Key information
31.9%
Earnings growth rate
31.5%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | 28.5% |
Return on equity | -3.8% |
Net Margin | -4.5% |
Next Earnings Update | 28 Aug 2024 |
Recent past performance updates
Recent updates
Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?
Jun 26Analysts Just Shaved Their Porton Pharma Solutions Ltd. (SZSE:300363) Forecasts Dramatically
May 02Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?
Mar 26Porton Pharma Solutions Ltd.'s (SZSE:300363) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Mar 04Revenue & Expenses Breakdown
How Porton Pharma Solutions makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 2,967 | -132 | 653 | 371 |
31 Dec 23 | 3,667 | 267 | 658 | 452 |
30 Sep 23 | 4,854 | 880 | 793 | 492 |
30 Jun 23 | 5,460 | 1,203 | 807 | 549 |
31 Mar 23 | 6,970 | 1,928 | 871 | 578 |
01 Jan 23 | 7,035 | 2,005 | 841 | 520 |
30 Sep 22 | 6,293 | 1,741 | 712 | 489 |
30 Jun 22 | 5,763 | 1,522 | 668 | 409 |
31 Mar 22 | 4,005 | 818 | 514 | 301 |
01 Jan 22 | 3,105 | 524 | 430 | 262 |
30 Sep 21 | 2,614 | 446 | 367 | 265 |
30 Jun 21 | 2,402 | 408 | 336 | 224 |
31 Mar 21 | 2,224 | 364 | 316 | 188 |
31 Dec 20 | 2,072 | 324 | 307 | 155 |
30 Sep 20 | 1,958 | 289 | 306 | 142 |
30 Jun 20 | 1,852 | 251 | 295 | 120 |
31 Mar 20 | 1,689 | 217 | 280 | 126 |
31 Dec 19 | 1,551 | 186 | 241 | 117 |
30 Sep 19 | 1,430 | 163 | 185 | 99 |
30 Jun 19 | 1,299 | 159 | 175 | 92 |
31 Mar 19 | 1,225 | 119 | 180 | 78 |
31 Dec 18 | 1,185 | 124 | 188 | 73 |
30 Sep 18 | 1,191 | 134 | 188 | 84 |
30 Jun 18 | 1,101 | 79 | 161 | 113 |
31 Mar 18 | 1,039 | 73 | 148 | 92 |
31 Dec 17 | 1,184 | 107 | 169 | 73 |
30 Sep 17 | 1,242 | 121 | 223 | 53 |
30 Jun 17 | 1,307 | 138 | 257 | 0 |
31 Mar 17 | 1,399 | 182 | 260 | 0 |
31 Dec 16 | 1,327 | 171 | 250 | 0 |
30 Sep 16 | 1,194 | 148 | 199 | 0 |
30 Jun 16 | 1,097 | 148 | 196 | 0 |
31 Mar 16 | 1,029 | 125 | 164 | 0 |
31 Dec 15 | 1,021 | 110 | 164 | 0 |
30 Sep 15 | 1,155 | 142 | 194 | 0 |
30 Jun 15 | 1,156 | 138 | 182 | 0 |
31 Mar 15 | 1,072 | 127 | 194 | 0 |
31 Dec 14 | 987 | 125 | 185 | 0 |
30 Sep 14 | 719 | 71 | 163 | 0 |
30 Jun 14 | 739 | 88 | 159 | 0 |
31 Mar 14 | 723 | 90 | 150 | 0 |
31 Dec 13 | 734 | 100 | 144 | 0 |
Quality Earnings: 300363 is currently unprofitable.
Growing Profit Margin: 300363 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300363 is unprofitable, but has reduced losses over the past 5 years at a rate of 31.9% per year.
Accelerating Growth: Unable to compare 300363's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 300363 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.8%).
Return on Equity
High ROE: 300363 has a negative Return on Equity (-3.84%), as it is currently unprofitable.